Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Interest & Investment Income (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Interest & Investment Income readings, the most recent being $3.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 3.12% year-over-year to $3.5 million, compared with a TTM value of $13.1 million through Dec 2025, up 2.9%, and an annual FY2025 reading of $13.1 million, up 2.9% over the prior year.
  • Interest & Investment Income hit $3.5 million in Q4 2025 for Apellis Pharmaceuticals, down from $4.4 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $6.0 million in Q2 2023, with the low at $37000.0 in Q4 2021.
  • Median Interest & Investment Income over the past 5 years was $3.0 million (2024), compared with a mean of $2.8 million.
  • The sharpest move saw Interest & Investment Income tumbled 94.11% in 2021, then surged 12264.86% in 2022.
  • Year by year, Interest & Investment Income stood at $37000.0 in 2021, then skyrocketed by 12264.86% to $4.6 million in 2022, then fell by 0.59% to $4.5 million in 2023, then fell by 25.33% to $3.4 million in 2024, then increased by 3.12% to $3.5 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $3.5 million, $4.4 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.